Text Size

Transitions: Linkages From Jail To Community

This study is currently recruiting participants.
Verified June 2011 by Yale University
Sponsor:
Information provided by:
Yale University
ClinicalTrials.gov Identifier:
NCT00841711
First received: February 10, 2009
Last updated: June 30, 2011
Last verified: June 2011
History of Changes
  Purpose

TRANSITIONS, a novel jail-release program for People Living with HIV/AIDS (PLWHA), will use evidence-based interventions and adapt them to create a comprehensive transitional program in Waterbury and New Haven County, Connecticut. Evidence-based interventions will include, but not be limited to, enhanced rapid HIV testing within the New Haven Community Correctional Center (NHCCC, local jail), intensive case management, continuity of buprenorphine treatment from the jail to the community setting and a novel Money Management (MM) program.

The HIV in Prisons Program and the Community Health Care Van (CHCV) at the Yale University AIDS Program, in collaboration with the Connecticut Department of Correction and the Waterbury Hospital Infectious Diseases Clinic, propose to expand the availability of opiate substitution treatment and to enhance clinical and social services for PLWHA, who are transitioning from the jail to the community setting.

As part of Transitions, we will develop a model Money Management program that we have used in community settings to improve health outcomes for socially and medically marginalized populations and adapt it for a jail-release program. The Transitions program will incorporate these elements into a combined intervention and will result in a clinical trial to compare the additional contribution of a money management program.


Condition Intervention Phase
HIV
Substance Abuse
HIV Infections
 Behavioral: Intensive Case Management
Drug: Buprenorphine
Behavioral: Money Management
 Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: Transitions: Linkages From Jail to Community

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Further study details as provided by Yale University:

Primary Outcome Measures:
  • Substance use outcomes measured by self-report [ Time Frame: weekly reporting ] [ Designated as safety issue: No ]
  • Urine toxicology results [ Time Frame: weekly report ] [ Designated as safety issue: No ]

Estimated Enrollment: 65
Study Start Date: September 2008
Estimated Study Completion Date: August 2012
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Behavioral: Intensive Case Management
    Transitions involves the integration of evidence-based interventions, intensive case management that incorporates outreach elements similar to assertive community treatment (ACT). Intensive case management goes beyond the tenets of case management and incorporates community outreach. This model of case management has its roots in assertive community treatment (ACT) and has demonstrated a 37% greater reduction in homelessness and a 26% greater improvement in psychiatric symptom severity compared with standard case management treatments. As such, intensive case management is likely to result in important outcomes for the target population, is evidence-based and has been validated in prison-release programs.
    Drug: Buprenorphine
    All participants that have a history of opiate dependency and need treatment with opiate substitution therapy will be offered Buprenorphine as an option for their substance use. For those who need additional or more structured treatment will be referred to methadone maintenance program.
    Behavioral: Money Management
    All participants will be offered money management as a component for further assistance to this population who need financial management services in order to stabilize them and help with the transition back into the community upon release from incarceration.
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HIV Seropositive
  • 18 years of age or older
  • male and female
  • incarcerated but not sentenced inmates
  • releasing to New Haven area
  • releasing to Waterbury area
  • within 30 days post release from jail

Exclusion Criteria:

Not meeting inclusion criteria

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00841711

Contacts
Contact: Ruthanne Marcus, MPH 203-764-9958 ruthanne.marcus@yale.edu
Contact: Maua Herme, MPH maua.herme@yale.edu

Locations
United States, Connecticut
Yale Clinical Research Recruiting
New Haven, Connecticut, United States, 06510
Contact: Ruthanne Marcus, MPH     203-764-9958     ruthanne.marcus@yale.edu    
Principal Investigator: Frederick Altice, MD            
Waterbury Hosp ID Clinic Recruiting
Waterbury, Connecticut, United States, 06708
Contact: Maria Rodriguez, BS     203-228-9112     mrodriguez@wtbyhosp.org    
Principal Investigator: Frederick Altice, MD            
Sponsors and Collaborators
Yale University
Investigators
Principal Investigator: Frederick L Altice, MD Yale University
  More Information

No publications provided

Responsible Party: Professor, Frederick Altice, M.D., Yale University School of Medicine-AIDS Program
ClinicalTrials.gov Identifier: NCT00841711     History of Changes
Other Study ID Numbers: 0711003262, H97HA08541
Study First Received: February 10, 2009
Last Updated: June 30, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Yale University:
HIV
AIDS
Buprenorphine
Intensive Case Management
Money Management
 Rapid Testing
Substance Abuse
Opioid Dependance
Inmate Population

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Substance-Related Disorders
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Agents
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
 Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Mental Disorders
Buprenorphine
Analgesics, Opioid
Analgesics
Pharmacologic Actions
Therapeutic Uses
Central Nervous System Depressants
Narcotic Antagonists
Narcotics

ClinicalTrials.gov processed this record on May 22, 2013